NASDAQ:AVRO AVROBIO (AVRO) Stock Price, News & Analysis → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Free AVRO Stock Alerts $1.21 +0.02 (+1.68%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$1.18▼$1.2250-Day Range$1.19▼$1.3452-Week Range$0.57▼$1.70Volume204,967 shsAverage Volume114,772 shsMarket Capitalization$54.28 millionP/E RatioN/ADividend YieldN/APrice Target$2.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get AVROBIO alerts: Email Address AVROBIO MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside65.3% Upside$2.00 Price TargetShort InterestHealthy0.36% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom $0.58 to ($0.48) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.41 out of 5 starsMedical Sector712th out of 913 stocksBiological Products, Except Diagnostic Industry124th out of 154 stocks 3.0 Analyst's Opinion Consensus RatingAVROBIO has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageAVROBIO has received no research coverage in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted0.36% of the float of AVROBIO has been sold short.Short Interest Ratio / Days to CoverAVROBIO has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in AVROBIO has recently decreased by 4.19%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAVROBIO does not currently pay a dividend.Dividend GrowthAVROBIO does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AVRO. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for AVROBIO this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for AVRO on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added AVROBIO to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, AVROBIO insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.20% of the stock of AVROBIO is held by insiders.Percentage Held by Institutions62.63% of the stock of AVROBIO is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for AVROBIO are expected to decrease in the coming year, from $0.58 to ($0.48) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AVROBIO is -12.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AVROBIO is -12.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAVROBIO has a P/B Ratio of 0.57. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsBetter than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> About AVROBIO Stock (NASDAQ:AVRO)AVROBIO, Inc., a clinical-stage gene therapy company, develops hematopoietic stem cell gene therapies to treat rare diseases in the United States. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The company's pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1 and 3; AVR-RD-01, which is in phase 2 clinical trials for the treatment of Fabry disease; and AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Read More AVRO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AVRO Stock News HeadlinesApril 22, 2024 | bizjournals.comDeal watch: Biopharma M&A more than doubled in Q1March 26, 2024 | wsj.comAVROBIO Inc.April 27, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.February 23, 2024 | ca.finance.yahoo.comAVRO Apr 2024 2.500 callFebruary 18, 2024 | finance.yahoo.comAVRO May 2024 2.500 callFebruary 14, 2024 | businesswire.comAVROBIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of AVROBIO, Inc. - AVROJanuary 31, 2024 | stockhouse.comShareholder Alert: Ademi LLP investigates whether AVROBIO, Inc. has obtained a Fair Price in its transaction with TectonicJanuary 31, 2024 | bizjournals.comFive things: Vertex's new drug, a reverse merger, and how are you doing?April 27, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.January 31, 2024 | msn.comAvrobio Inc Announces Executive Team Changes and AppointmentsJanuary 30, 2024 | bizjournals.comAvrobio to take Watertown biotech public via reverse mergerJanuary 30, 2024 | stockhouse.comSHAREHOLDER NOTICE: Halper Sadeh LLC Investigates AVRO, CALB, BCALJanuary 30, 2024 | msn.comAvrobio to buy 100% equity interests of Tectonic TherapeuticJanuary 30, 2024 | marketwatch.comAvrobio Shares Dive 17% After Tectonic Therapeutic DealJanuary 30, 2024 | finance.yahoo.comAVROBIO and Tectonic Therapeutic Announce MergerDecember 20, 2023 | benzinga.comAvrobio Stock (NASDAQ:AVRO), Analyst Ratings, Price Targets, PredictionsDecember 19, 2023 | msn.comMizuho Downgrades AVROBIO (AVRO)December 19, 2023 | benzinga.comAvrobio Stock (NASDAQ:AVRO) Dividends: History, Yield and DatesDecember 18, 2023 | realmoney.thestreet.comAvrobio just downgraded at Mizuho, here's whyNovember 14, 2023 | morningstar.comAvrobio Inc AVRONovember 14, 2023 | markets.businessinsider.comPotential Growth and Strategic Alternatives: Reasons Behind Zhu’s Buy Rating for AvrobioNovember 8, 2023 | finance.yahoo.comIs AVROBIO (AVRO) Stock Outpacing Its Medical Peers This Year?October 6, 2023 | finance.yahoo.comHas AVROBIO (AVRO) Outpaced Other Medical Stocks This Year?October 5, 2023 | msn.comAvroBio (AVRO) Price Target Increased by 12.82% to 3.74September 25, 2023 | ca.finance.yahoo.comAVROBIO, Inc. (AVRO)September 11, 2023 | benzinga.comSolu Therapeutics Appoints Philip Vickers, Ph.D., as President and Chief Executive OfficerAugust 12, 2023 | msn.comAvrobio: Net-Net Biotech Pursuing Strategic AlternativesSee More Headlines Receive AVRO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AVROBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/04/2021Today4/27/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:AVRO CUSIPN/A CIK1681087 Webwww.avrobio.com Phone(617) 914-8420FaxN/AEmployees13Year FoundedN/APrice Target and Rating Average Stock Price Target$2.00 High Stock Price Target$2.00 Low Stock Price Target$2.00 Potential Upside/Downside+65.3%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.10) Trailing P/E RatioN/A Forward P/E Ratio2.09 P/E GrowthN/ANet Income$12.16 million Net MarginsN/A Pretax MarginN/A Return on Equity-74.86% Return on Assets-65.11% Debt Debt-to-Equity RatioN/A Current Ratio15.78 Quick Ratio15.78 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash Flow$0.29 per share Price / Cash Flow4.14 Book Value$2.13 per share Price / Book0.57Miscellaneous Outstanding Shares44,860,000Free Float40,734,000Market Cap$54.28 million OptionableOptionable Beta1.22 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Erik John Ostrowski M.B.A. (Age 52)President, Interim CEO, CFO & Treasurer Comp: $1.25MDr. Azadeh Golipour Ph.D. (Age 44)Chief Technology Officer Comp: $1.01MDr. Essra Ridha FFPM (Age 41)M.D., Chief Medical Officer Comp: $1.12MMr. Jeffrey Medin Ph.D.Scientific FounderMr. Steven N. Avruch J.D. (Age 62)Chief Legal Officer & Secretary Comp: $506.68kMr. Scott GottesmanVice President of Human ResourceMs. Kirsten DupuisChief of StaffMore ExecutivesKey CompetitorsLENZ TherapeuticsNASDAQ:LENZJATT AcquisitionNYSE:JATTQuince TherapeuticsNASDAQ:QNCXCidara TherapeuticsNASDAQ:CDTXAligos TherapeuticsNASDAQ:ALGSView All CompetitorsInstitutional OwnershipVazirani Asset Management LLCBought 181,727 shares on 2/14/2024Ownership: 1.458%GABELLI & Co INVESTMENT ADVISERS INC.Bought 353,000 shares on 2/13/2024Ownership: 0.792%Gabelli Funds LLCBought 343,421 shares on 2/13/2024Ownership: 0.771%View All Institutional Transactions AVRO Stock Analysis - Frequently Asked Questions Should I buy or sell AVROBIO stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AVROBIO in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" AVRO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AVRO, but not buy additional shares or sell existing shares. View AVRO analyst ratings or view top-rated stocks. What is AVROBIO's stock price target for 2024? 2 brokerages have issued 1-year price targets for AVROBIO's shares. Their AVRO share price targets range from $2.00 to $2.00. On average, they expect the company's stock price to reach $2.00 in the next twelve months. This suggests a possible upside of 65.3% from the stock's current price. View analysts price targets for AVRO or view top-rated stocks among Wall Street analysts. How have AVRO shares performed in 2024? AVROBIO's stock was trading at $1.36 at the beginning of 2024. Since then, AVRO shares have decreased by 11.0% and is now trading at $1.21. View the best growth stocks for 2024 here. Are investors shorting AVROBIO? AVROBIO saw a increase in short interest in March. As of March 31st, there was short interest totaling 143,200 shares, an increase of 14.6% from the March 15th total of 125,000 shares. Based on an average daily volume of 299,800 shares, the short-interest ratio is presently 0.5 days. Currently, 0.4% of the company's stock are short sold. View AVROBIO's Short Interest. When is AVROBIO's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our AVRO earnings forecast. How were AVROBIO's earnings last quarter? AVROBIO, Inc. (NASDAQ:AVRO) posted its quarterly earnings data on Thursday, November, 4th. The company reported ($0.75) EPS for the quarter, meeting analysts' consensus estimates of ($0.75). What other stocks do shareholders of AVROBIO own? Based on aggregate information from My MarketBeat watchlists, some companies that other AVROBIO investors own include Sorrento Therapeutics (SRNE), ImmunoGen (imgn), Aduro Biotech (ADRO), Aldeyra Therapeutics (ALDX), Amarin (AMRN), Biohaven (BHVN), Nabriva Therapeutics (NBRV), Selecta Biosciences (SELB), VBI Vaccines (vbiv) and Arbutus Biopharma (ABUS). When did AVROBIO IPO? AVROBIO (AVRO) raised $75 million in an IPO on Thursday, June 21st 2018. The company issued 4,400,000 shares at $16.00-$18.00 per share. Morgan Stanley, Cowen and Wells Fargo Securities acted as the underwriters for the IPO and Wedbush Securities was co-manager. How do I buy shares of AVROBIO? Shares of AVRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AVRO) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyProtect Your Bank Account Before It’s Too LateWeiss RatingsDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThey say it’s ‘unstoppable’ – How I made 43,509% Investing Daily Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AVROBIO, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
